Trump Administration to Announce New Drug Pricing Deals With Bayer, Takeda

The Trump administration is expected to announce a new round of drug-pricing agreements on Monday, expanding its initiative to make prescription medicines more affordable for Americans. A White House official confirmed the plan, with an event on healthcare affordability scheduled for 3 p.m. ET.

New Agreements Expected

Several international and mid-sized pharmaceutical companies are expected to be part of the announcement. According to The Financial Times, which cited two people familiar with the matter, the new deals will include:

• Germany-based Bayer
• Japan's Takeda Pharmaceutical
• Australia-based CSL
• Several other mid-size biotech firms

These agreements build on a program the administration started last year, which secured pricing deals with 17 major drugmakers, including Pfizer, Eli Lilly, and Amgen. Those companies agreed to offer prices comparable to what is paid in other developed countries, a model known as "most-favored-nation" pricing, in exchange for benefits such as tariff relief.

Context and Market Impact

Ad

The initiative targets the high cost of prescription drugs in the United States, where patients often pay nearly three times more than in other developed nations. The administration has been pressuring the pharmaceutical industry to align U.S. prices more closely with international benchmarks.

However, the program has faced challenges in gaining broad participation, particularly from smaller drug companies. A Reuters report from June noted that many smaller and mid-sized firms had been slow to sign on, with some executives citing a lack of clear financial benefits. The new deals suggest the administration is making progress in expanding the program's reach.

Uncertain Savings and Political Timing

The ultimate financial impact of these deals on the government and patients remains unclear. Government health programs like Medicaid already receive substantial, legally mandated discounts from drug manufacturers. The White House has previously promoted a speculative figure, suggesting its broader drug pricing efforts could save $64.3 billion in federal and state spending over the next decade.

The announcement comes as the administration holds a series of high-profile events focused on healthcare costs. This public push on affordability is seen as a key theme ahead of this year's midterm elections, which will determine control of Congress.